Brief: J&J Says New Talvey Plus Darzalex Faspro Data Demonstrate Strength Of Bispecific Combination In Earlier-Line Relapsed Or Refractory Multiple Myeloma
13/06/2026 11:39
BRIEF-J&J Says New Talvey Plus Darzalex Faspro Data Demonstrate Strength Of Bispecific Combination In Earlier-Line Relapsed Or Refractory Multiple Myeloma June 13 (Reuters) - Johnson & Johnson JNJ.N:
NEW TALVEY® (TALQUETAMAB-TGVS) PLUS DARZALEX FASPRO® (DARATUMUMAB AND HYALURONIDASE-FIHJ) DATA DEMONSTRATE THE STRENGTH OF A BISPECIFIC COMBINATION IN EARLIER-LINE RELAPSED OR REFRACTORY MULTIPLE MYELOMA
JJ - SUBMITS SBLA TO FDA AND TYPE II VARIATION TO EMA FOR TALVEY COMBINATION
JJ - TALVEY PLUS DARZALEX FASPRO SHOWS CONSISTENT SAFETY PROFILE AND REDUCED SEVERE INFECTIONS
JJ - TALVEY PLUS DARZALEX FASPRO OUTPERFORMS STANDARD OF CARE IN PFS AND OS AT 24 MONTHS
Source text: ID:nPn3WhtRJa
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Johnson & Johnson
See all newsFactbox: Global drugmakers invest billions to boost US presence
Press Digest: British Business - June 15
Brief: J&J Says New Talvey Plus Darzalex Faspro Data Demonstrate Strength Of Bispecific Combination In Earlier-Line Relapsed Or Refractory Multiple Myeloma
Brief: UK's MHRA Authorises Nipocalimab To Treat Adults & Adolescents Aged 12 Years & Older With Generalised Myasthenia Gravis
Factbox: Major deals involving US drugmakers and biotechs over the past decade